Recent work suggests that chronic lymphocytic leukemia (B-CLL
Introduction
B cell chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of monoclonal B-lymphocytes, expressing CD5 and CD23 molecules and characteristically low amounts of surface membrane Ig and CD79b molecules. 1 It has been proposed that the normal counterpart of leukemic cells may be a mantle-zone B cell assumed to correspond to naive B cells expressing unmutated V genes. 2 However, more than half of B-CLL cases harbor somatic mutations of VH genes, 3 as if they had matured in a lymphoid follicle. In fact, unmutated V genes are associated with a markedly poorer prognosis, even within the good prognosis stage A group and predominate in advanced disease stages. [4] [5] [6] These studies postulated that B-CLL cells might originate from two different stages of B cell development, ie pre or post-GC (germinal center) B cells.
Pascual et al 7 proposed that IgD and CD38, in conjunction with CD23, CD77 and Ig isotype, could be used to classify human mature B-lymphocytes into at least five subsets. Thus, IgD + CD38 − normal tonsillar B cells corresponding to naive or virgin B cells, display unmutated V H genes and are located in the follicular mantle. In contrast, the IgD − CD38 + subset is extensively mutated and corresponds to germinal center B cells (centroblasts and centrocytes). Finally, memory B cells are enriched among IgD and CD38 double-negative B cells. On this basis, an investigation has been carried out to determine whether a normal counterpart for the malignant cell could exist.
Despite expressing mutated V genes in more than half of patients, [3] [4] [5] [6] the majority of B-CLL cells co-express both IgM and IgD, [8] [9] [10] while a minority express exclusively IgM and a few express other isotypes such as IgG and IgA. [11] [12] [13] In addition, switching events leading to additional isotypes have been shown in B-CLL cells using analysis of RNA transcripts, 14 as well as double isotype IgM/IgG and IgM/IgA membrane expression. 11, 12 These results suggest that B-CLL cells are able to mutate and to undergo isotype switch, while keeping IgD expression. Dual isotype expression has also been described at the level of transcription in normal human B cells 15 and in different B cell tumors, [16] [17] [18] [19] though the molecular mechanism implicated in this event remains unclear.
To further investigate this issue and define the mechanism involved in dual isotype expression, we have studied the complete V H nucleotide sequence and the presence of RNA transcripts from different C H domains in 25 B-CLL patients. In addition, we have characterized membrane Igs in B-CLL cells displaying double isotype expression and examined the putative mechanism involved at the DNA level. Our results demonstrate that: (1) expression of IgD is not related to the mutational frequency and activation of the isotype switch pathway; (2) in a small percentage of patients, isotype switch, leading to simultaneous membrane expression of IgM, IgD, IgG and/or IgA, occurs and (3) this co-expression of different isotypes was accounted for by either a VDJ gene duplication or an RNA splicing mechanism. Overall, these results raise the question of whether B-CLL cells expressing unmutated and mutated V genes do indeed correspond respectively to naive and memory B cells.
Materials and methods

Patients
After informed consent, peripheral blood was obtained from 25 patients (identified as 01-25 in Table 1 cDNA preparation and genomic DNA isolation RNA was isolated by TriPure Isolation Reagent (Boehringer, Mannheim, Germany) from 5 × 10 6 PBMC. cDNA synthesis was performed in 20 l reaction volumes at 42ºC for 60 min using an oligo dT primer, 200 U of Moloney murine leukemia virus reverse transcriptase and 0.5 mM of each deoxyribonucleotide (Gibco, BRL, Bethesda, MD, USA). Genomic DNA of patients 01 and 07 was isolated by treatment overnight at 37ºC with 0.1 M EDTA, 20 g/ml of pancreatic Rnase, DNase free (Roche Diagnostics, Mannheim, Germany), 0.5% SDS, 10 mM Tris-HCl and 100 g/ml of proteinase K (Sigma-Aldrich, Paris, France) and later purified as previously described by Sambrook et al. 20 
PCR amplification
Ig family RT-PCR amplification using 5Ј-V H primers wich are leader specific for each of the V H 1 to V H 7 families together with a consensus J H primer in 3Ј region was carried out from cDNA, as previously described. 21 To define the 3Ј region of clonal transcripts, specific isotype 3Ј primers ( Figure 1 and Table 2 ) were selected based on the classification according to Kabat et al 22 and used together with 5Ј-primer specific tumorrelated V H sequence families. PCR protocol included 30 cycles of amplification (95ºC 30 s, 62ºC 30 s, 72ºC 1 min).
The 'long range PCR reaction' with genomic DNA of flow 
Table 2
Primers used for PCR amplifications Name and location Orientation Sequence (5Ј-3Ј) 
Analysis of genomic DNA in double isotype expressing cells
After identification of V H sequences of patients 01 and 07, specific 5Ј primers were designed (CDR2/Fow-01 and CDR1/Fow-07 in Figure 1 and Table 2 ). Double expressing IgM and IgG B-CLL cells from patients 01 and 07 were isolated by flow-cytometry (purity of 98% in both patients). Genomic DNA was isolated and 'long range PCR reaction' was performed. Amplification products were migrated in 0.6% agarose gel, transferred to nylon membranes (Schleicher and Schuell; Dassel, Germany) and then hybridized with specific probes. (a) Probe , 820 bp, corresponded to the product obtained with primers /Fow-C H 1 and /Rev-C H 3; (b) probe ␥, 1.4 kb corresponded to the product obtained with primers ␥/Fow-CH1 and ␥/Rev-CH3); and (c) specific tumoral probes from CLL-01 (205 pb) and CLL-07 (245 pb) were constructed using clone sequence specific CDR2/Fow-01/CDR3/Rev-01 and CDR1/Fow-07/CDR3/Rev-07, respectively ( Table 2 ). All probes were labeled with [␣-32 P] dCTP (ICN, Biomed, Orsay, France) by random priming and hybridized to the membranebound PCR product. Hybridization was carried out at 65ºC as previously described by Havouis et al 23 . Filters were washed three times for 15 min with 0.1 SSC and 0.1% SDS at 65ºC and exposed to Hyper Film MP (Amersham, Pharmacia, Biotech UK, Buckinghamshire, UK) at −80ºC.
Nested PCR amplification
Amplified DNA of patients 01 and 07 (dilution 1/1000) using the 'long range PCR reaction' was used as template for a nested PCR reaction with 5Ј primer CDR2/Fow-01 and 3Ј primer J H /Rev for patient 01 and CDR1/Fow-07 and 3Ј primer J H /Rev for patient 07 ( Figure 1 and Table 2 ). PCR protocol included 33 amplification cycles (95ºC 30 s, 65ºC 30 s, 72ºC 1 min).
Figure 2
Expression of and ␦ transcripts from 16 representative patients displaying mutated (8) and unmutated (8) V H genes. ␦ transcripts correspond to 400-480 bp fragments and transcripts to 500-550 bp run in a TBE 2% agarose gel. Numbers corresponding to Table 1 identify patients. MW, molecular weight. Table 1 
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Results
Almost all B-CLL patients whether expressing mutated or unmutated VH genes display and ␦ transcripts
In some CLL patients additional isotype transcripts were expressed by the tumoral clone
Of the 25 patients studied, ␥ transcripts could be detected by RT-PCR in 11 patients and ␣ transcripts in five patients. All patients expressing ␣ or ␥ co-expressed and ␦ transcripts (Table 1) . To determine whether the ␥ and ␣ transcripts had the same VDJ rearrangements as the B-CLL tumoral clone, we sequenced the 11 ␥ and the five ␣ detected transcripts. In nine out of the 11 patients expressing ␥ transcripts and four out of the five expressing ␣ transcripts, the sequences obtained were unrelated to those of the B-CLL tumoral clone (data not shown). However, genuine tumoral ␥ and ␣ B-CLL transcripts with identical sequences were found for patient 01 who expressed the V H 1-02 gene in an unmutated form and for ␥ transcripts from B-CLL 07 expressing an unmutated V H 4-34 gene (Figure 1) . The results show that some B-CLL patients are able to simultaneously express two or three different Ig transcript isotypes,
, while keeping ␦ transcript expression (Figure 3a and 3c, respectively) .
Both CLL patients expressing genuine ␥ together with and ␦ transcripts displayed membrane expression of these isotypes
To determine whether the , ␦, ␥ and ␣ transcripts were expressed and translated into IgM, IgD, IgG and IgA at the membrane level, flow cytometry experiments were performed (Figure 3b and d) . Since cytometry analysis and sorting experiments were carried out by double color labeling and almost all B-CLL cells from patients 01 and 07, co-expressed the membrane IgM and IgD, to proceed to the study of other Expression of additional isotypes from two tumoral CLL clones. mRNA transcript amplification of VDJ/C,VDJ/C␦,VDJ/C␥ and VDJ/C␣ from CLL 01 and 07, are shown in (a) and (c), respectively (2% agarose gel electrophoresis). Panels b and d depict flow cytometry display of IgM, IgG and IgA isotypes in B-CLL lymphocytes from patients 01 and 07 respectively. Surface analysis was performed by dual color staining with rabbit anti-human-chains F-(abЈ) 2 conjugated with phycoerythrin (PHYCO) combined with anti-human-␥ chains or anti-human-␣ chains F (abЈ) 2 (Figure 3d ). As control B-CLL cells from patients 11 and 16 were analyzed; these contained only and ␦ transcripts and were found to be negative for both IgG and IgA membrane expression (data not shown).
Different mechanisms are probably involved in coexpression of different isotypes in B-CLL cells
To better understand the mechanism involved in simultaneous isotype expression by B-CLL cells, these two patients were analyzed at the genomic level. Given the low quantity of cells co-expressing IgM, IgD and IgG in these patients, we employed the 'long range PCR reaction'. We amplified DNA from flow-cytometry purified cell subsets expressing IgM but not IgG, DNA from cells simultaneously expressing IgM/IgG and DNA from cells exclusively expressing IgG in the absence of IgM expression. Since these cell preparations were Ͼ98% pure, controls containing the corresponding number of cells expressing exclusively IgM or exclusively IgG from the same patient were analyzed in parallel (Figure 4a and e, lanes 9 and 10). In the case of patient 01, by using 5Ј clone primers and 3Ј /Rev-C H 3 and ␥/Rev-C H 3 primers, we could amplify both and ␥ fragments of approximately 7 and 7.8 kb from sorted IgM + or IgG + expressing cells respectively (Figure 4a,  lanes 1 and 3) . These amplifications correspond to the expected size for rearranged VDJ/C and VDJ/C␥ segments at the DNA level. 25, 26 In addition, and ␥ fragments of 7 and 7.8 kb respectively, from sorted cells co-expressing both isotypes were amplified (Figure 4a, lanes 5 and 6) . To confirm these results the amplification products were transferred to nitrocellulose membranes and hybridized with clone-specific, , and ␥ probes (Figure 4b-d) , respectively. Cells co-expressing IgM and IgG displayed two bands of 7 and 7.8 kb (lanes 5 and 6), respectively corresponding to VDJ/C and VDJ/C␥ amplifications, whereas for IgM + cells (lane 1) or IgG + cells (lane 3) only the VDJ/C and the VDJ/C␥ amplifications were respectively identified. A further confirmation of the clonal origin of these rearrangements was obtained by nested PCR experiments amplifying these fragments with tumoral specific CDR2/Fow-01 with J H probes and CDR1/Fow-07 with J H probes. Fragments of expected size (230 pb for patient 01 and 270 pb for patient 07) were amplified. The sequence of these fragments confirmed their clonal origin (Figure 1 ). Since in germinal DNA the distance between the VDJ rearrangement and more proximal 3Ј constant domains (C H -␥-3) exceeds 60 kb, 27 ,28 the presence of 7-8 kb fragments containing both the VDJ rearrangement and the C H domain, strongly suggests that a DNA duplication of the VDJ rearrangement occurred in patient 01. When the same experiment was carried out for patient 07, bands of approximately 7 and 8 kb were respectively observed in long range PCR reaction for IgM + cells and IgG + cells (Figure 4e, lanes 1 and 3) . As opposed to patient 01, only one band of 7 kb corresponding to a DNA VDJ/C rearrangement, could be amplified from IgM 
/IgG
+ cells. Lanes 7 and 8, DNA from human placental cells amplified by CDR 2/Fow-01, /Rev-C H 3 and CDR 2/Fow-01,␥/Rev-C H 3, respectively. Lane 9, control amplification with CDR 2/Fow-01 and /Rev-C H 3 primers in DNA corresponding to 2% cells expressing IgM but not IgG. Lane 10, control amplification with CDR 2/Fow-01 and ␥/Rev-C H 3 primers in DNA corresponding to 2% cells expressing exclusively IgG. MW, molecular weight. The amplified PCR products were subjected to electrophoresis in 0.6% TBE agarose gel. Panels b, f, c, g, d, and h depict results corresponding respectively to agarose gel fragments transferred into nitrocellulose membrane followed by incubation with specific patient's probe (b and f), specific region constant probe (c and g) and specific ␥ region constant probe (d and h). In lanes 5 and 6 from gel (a) DNA amplified fragments from cells co-expressing IgM and IgG isotypes are depicted. The 7.8 kb fragment observed in lane 6 corresponds to a DNA fragment amplified with primers corresponding to the VDJ rearrangement in 5Ј and to C-␥ in 3Ј. Given the genomic organization, this amplification can only be accounted for by gene duplication. In contrast, in the case of patient 07 we were unable to substantiate such amplification at the DNA level (e) for cells co-expressing IgM and IgG, which indicates that gene duplication, cannot be invoked in this case.
( Figure 4e, lane 5) . Moreover, when hybridization experiments were performed on these amplified fragments similar results were found (Figure 4f-h) . These results may suggest that in B-CLL cells from patient 07, simultaneous expression of IgM and IgG appears consistent with the possibility that RNA transcripts containing different isotypes within the same cell is occurring.
Discussion
B cell development can be conveniently divided into an antigen-independent and an antigen-dependent phase. The antigen-independent phase mainly takes place in the bone marrow, where B cell precursors undergo a rearrangement of the different variable gene segments and the initial antibody repertoire is developed. Since these cells have not been exposed to antigen or to T cells in germinal centers, their heavy and light chain genes display no somatic mutations. 29 Naive B cells leave the bone marrow and enter the peripheral blood as IgM + /IgD + cells. In the germinal center, the antigen-dependent stage of B cell development takes place. The sequence and structure of the antigen-binding site can be altered through a process of somatic hypermutation that is targeted at the V domain, leading to a change in the binding affinity and specificity of the antibody. [30] [31] [32] In addition, a second type of recombination event, termed class switch recombination, occurs in the germinal centers this allows the B cell to change the antibody effector function, while maintaining the antigen specificity of the original antibody 33 . Different possibilities can be proposed to determine the normal counterpart of B-CLL cells. As CLL B cells usually express IgM, IgD and CD5, they were initially considered as B1 cells.
Leukemia
However, in contrast to normal B1 cells, known to express high levels of IgM, B-CLL cells poorly express it. Since CLL phenotype does not fit with classical B1 cells, the possibility also exists as previously proposed by Wortis et al. 34 that B-CLL CD5
+ cells could derive from conventional B2 cells, induced to express CD5 following an as yet unknown stimulation. Intriguingly, more than half of B-CLL patients express V genes harboring somatic mutations. According to the classification of normal B cells designed by Pascual et al, 7 expression of CD38 is related to the entry of the cell into the germinal center and one should expect expression of CD38 in cells undergoing an active mutational process. 5, 7 In contrast with this prediction, B-CLL cells expressing CD38 are more frequently observed among unmutated cases. 5 Furthermore, almost constant expression of CD27 in B-CLL cells has been associated with a memory phenotype. 35 This difficulty in attributing a normal counterpart to the B-CLL cells may be accounted for by the fact that B-CLL cells are tumoral cells. The possibility that this 'atypical' expression of some marker proteins could occur as a consequence of genetic abnormalities occurring during leukemic transformation and to the presence of an activated phenotype 36 among these tumoral cells, cannot be ruled out. Alternatively, other possibilities can be discussed to explain the contradiction between phenotypic markers and the absence of mutations in Ig genes: (1) The clear-cut distinction in the mutation profile of Ig genes in B-CLL cells has also led to hypothesize that B-CLL may include two separate malignancies: one derived from an Ig-unmutated naive cell and associated with poor prognosis, whereas the other, derived from an Ig-mutated B cell that has passed through the germinal center, is associated with good prognosis. [4] [5] [6] However, recent data derived from gene expression profiling analysis failed to clearly distinguish unmutated and mutated cases and favor the view that all cases of B-CLL have a common cell origin and/or a common malignant transformation mechanism. 37, 38 In addition, gene expression profiling of B-CLL cells expressing unmutated V genes was found to be closer to that of normal memory B cells than of normal naive B cells. 37 Our results demonstrate that B-CLL cells almost always express IgD irrespectively of the mutational pattern of Ig V genes. In addition, we demonstrate here that at least in some cases, cells expressing unmutated genes can proceed to isotype switch, traditionally considered to occur in the germinal center. 33 These data associated with new information arising from gene expression profiling, favors the view that B-CLL cells expressing unmutated V genes do not correspond to naive B cells. 38 2, 3, 39 This distinction could also be supported by the observation that length of CDRIII region and Ig variable region usage differ between the two subgroups, 39, 40 suggesting that the antigen recognized by mutated B-CLL cells and unmutated B-CLL cells may be of a different nature. Furthermore, B-CLL cells typically express low intensity surface immunoglobulins, which could be the consequence of a prior contact of these cells with an antigen. 41 The presence of an IgM
+ B cell subset with somatically mutated Ig receptors has been described among X-linked hyper-IgM patients. These patients are remarkable because they do not express a functional CD40 ligand, cannot switch Ig isotype and do not form germinal centers and memory B cells. These results could imply that these cells expand and diversify their Ig receptors in the absence of classical cognate T-B collaboration and raise the possibility that a separate diversification pathway could exist. 42, 43 Although, it is presently unclear where this putative separate pathway is located and whether it could exist in B-CLL, as postulated by recent work, 44 in a pseudofollicular microenvironment where infiltrating autologous T cells can provide CD40 stimulation and cytokines.
We report here two B-CLL cases whose B cells displayed unmutated V H genes, while being in an active switching process, since we could identify using flow cytometry and molecular biology experiments, the existence of a predominant IgM + IgD + population associated with minor populations expressing either IgM, IgD, IgG B cells or exclusively IgG for both patients and discrete subsets expressing IgM, IgD, IgA or exclusively IgA cells in the case of patient 01. The possibility that these results could be explained by contamination of sorted cells by small populations of IgM + or IgG + cells, was ruled out by amplifying DNA from absolute numbers of these purified cell populations (IgM + or IgG + ) corresponding to the percentages of putative contaminant cells (see Figure 4 , lanes 9 and 10). These results favor the view that these clonally related B cells could be arrested at different steps of differentiation. However, both cases displayed an identical unmutated profile, while an ongoing switch process was occurring, as we have previously reported in one case of immunocytoma. 45 To explain double isotype expression and the switch leading to additional isotype expression, three main models have been proposed. The first involves differential splicing of long primary transcripts with a single V H and multiple C H sequences. 46, 47 The second model postulates the existence of trans-splicing between V H /C and other germline sterile C H transcripts. 15, 17, 48 Finally, Mizuta et al 18 have also proposed the duplication of the VDJ gene and its replacementintegration into the S␥1/region and suggested that this could result from a sister chromatid exchange mechanism.
Our results, demonstrating in the case of patient 01 the existence of two DNA fragments containing, respectively, the same VDJ domain but associated to either C or C␥ regions strongly favor the view that VDJ duplication occurred in this case. In contrast, only fragments containing the specific VDJ/C could be amplified in the case of the IgM + /IgG + subset from patient 07. These results probably exclude the possibility that a VDJ duplication could occur and double expression of different isotypes in theses B-CLL cells could result as a consequence of long nuclear transcript splicing 46, 47 or of a transsplicing mechanism. 15, 17 In conclusion, our results demonstrate that B-CLL cells very frequently simultaneously express IgM and IgD, and that this expression is not related a mutation pattern of V genes. They also show that in a minority of cases (two out of 25) an active switch process involving the tumoral cell is also occurring and that at least in the two cases reported here, this switch process was not related to the mutation process. As concerns the switching mechanism leading to additional isotype expression, our results show that different mechanisms such as VDJ duplication and trans-splicing of this VDJ/C and other C H germline transcript or RNA splicing of long nuclear transcripts can be involved. Taken together, our results also point to the difficulty in assigning a normal counterpart to B-CLL cells and raise the possibility that a different B cell development pathway independent from classical germinal centers could be involved in B-CLL.
